Study Comparing NALIRINOX Plus PD-1 and Radiotherapy Versus Gemcitabine Plus Albumin-Paclitaxel With PD-1 and Radiotherapy for First Treatment of Locally Advanced Pancreatic Cancer

What this Trial Is About

Researchers are evaluating the effectiveness and safety of two treatment combinations as first-line therapy for patients with locally advanced pancreatic cancer. The study compares NALIRINOX combined with PD-1 synchronous sequential stereotactic body radiotherapy SBRT to gemcitabine plus albumin-paclitaxel combined with PD-1 synchronous sequential SBRT. The purpose is to determine which treatment approach may better control the cancer and improve patient outcomes. Participants receive one of two drug combinations Nal-IRI, Oxaliplatin, 5-FULV plus PD-1 or gemcitabine plus albumin-paclitaxel plus PD-1. These drugs are administered in cycleseither every 28 days days 1 and 15 for 6 to 8 cycles or every 21 days days 1 and 8 for 6 to 8 cycles depending on the group. SBRT is given during the third treatment cycle in both groups. During the study, participants will be closely monitored through assessments including progression-free survival up to 12 months and overall survival up to 24 months. The research team will also evaluate objective response rate and disease control rate within 12 months. Participants undergo regular check-ups and imaging to measure treatment response and safety. The total study duration and follow-up allow researchers to gather detailed information on how the treatments perform and their impact on participant health.

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer